$ABOS
Acumen Pharmaceuticals, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
$2.63
▲+2.33%+$0.060
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateAcumen Pharmaceuticals, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is ABOS up today? It is at $2.63 (+2.33%), and our scanner flagged it 15 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment ABOS spikes, and full due diligence on ABOS — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $ABOS 15 times in the last 30 days. Create a free account to track $ABOS, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on ABOS from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for ABOS today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Porter Derrell Director | Sold (automatic/other) | -13K 0.02% of company | sold 27% | 36K | $30K at $2.33 | Jun 17, 26 |
Porter Derrell Director | Other | 13K 0.02% of company | added 37% | 49K | $14K at $1.07 | Jun 17, 26 |
Porter Derrell Director | Sold (automatic/other) | -13K 0.02% of company | sold 27% | 36K | $30K at $2.33 | Jun 16, 26 |
Porter Derrell Director | Sold (automatic/other) | -6K | sold 12% | 48K | $15K at $2.35 | Jun 15, 26 |
Porter Derrell Director | Other | 6K | added 13% | 55K | $7K at $1.07 | Jun 15, 26 |
Fountain Nathan B Director | Sold (automatic/other) | -6K | sold 12% | 48K | $14K at $2.23 | Jun 9, 26 |
Stoppel Laura Director | Acquired (grant/award) | +36K 0.05% of company | added 100% | 48K | n/a | Jun 3, 26 |
Golumbeski George Director | Acquired (grant/award) | +36K 0.05% of company | n/a | 36K | n/a | Jun 3, 26 |
Ives Jeffrey L. Director | Acquired (grant/award) | +36K 0.05% of company | added 100% | 48K | n/a | Jun 3, 26 |
Porter Derrell Director | Acquired (grant/award) | +36K 0.05% of company | added 100% | 48K | n/a | Jun 3, 26 |
Stalfort John A Iii Director | Acquired (grant/award) | +36K 0.05% of company | added 19% | 221K | n/a | Jun 3, 26 |
Drapkin Kimberlee C Director | Acquired (grant/award) | +36K 0.05% of company | added 100% | 48K | n/a | Jun 3, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in biological products, (no diagnostic substances), closest in size first.
Here is the latest on ABOS from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for ABOS today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
ABOS last traded at $2.63, up 2.33% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Acumen Pharmaceuticals, Inc. Common Stock (ABOS) is next expected to report earnings on Wednesday, November 11, 2026, about 52 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The ABOS Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged ABOS 15 times in the last 30 days.
ABOS (Acumen Pharmaceuticals, Inc. Common Stock) trades on XNAS, with a market cap of about $192M in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge ABOS for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$ABOS discussion
Sign in to ask a question or join the discussion.